Skip to main content
  • Policy
    Get Involved
    Join BIOAction
    View Advocacy Toolkit
    Patient Advocacy
    Human Health
    Cost and Value of Biopharmaceuticals
    Antimicrobial Resistance
    Vaccines & Biodefense
    Drug Development & Review
    International
    Global Markets & Trade
    Multilateral Organizations
    Intellectual Property
    National Security
    Science & Regulatory
    All Policy
    Patient Advocacy

    Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access.

  • Member
    Membership Options
    Become a BIO Member
    Member Directory
    Have a Voice
    Membership Eligibility
    Member Toolkit
    Benefits By Sector
    .
    Human Health
    Startups
    .
    Non-R&D Companies
    Member Savings
    VWR, Part of Avantor
    75% off Lab Supplies
    Save with BIO
    Save with BIO
  • News & Insights
    Latest biotech news
    Popular blogs
    Events
    Policy
    BIO Statements
    Press Releases
    Letters, Testimony & Comments
    Amicus Briefs
    BIO Reports
    Industry Analysis Reports
    Biotech Jobs
    Economic Development Best Practices
    BIO Briefly
    Issue Briefs
    BIO.News
    I am BIO Podcast
    All News & Insights

    Sign up for the BIO.News Newsletter >

  • Events
    Event Portfolio
    Business Development
    Health
    International
    Professional Development
    Members Only
    All Events
    BIO International Convention

    June 22-25, 2026 | San Diego, CA

    Learn More
    BIO Investor Forum
    BIO Asia-Taiwan

    July 15-19, 2026
    Taipei, Taiwan

    BIO Patient & Health Advocacy Summit
    BIO Patient Advocacy Changemakers Event

    October 22-23, 2026
    Washington, D.C

    BIO Asia-Taiwan
    BIO Europe

    November 9-11, 2026
    Cologne, Germany

    BIO Webinars

    Explore the webinar opportunities for interactive, online learning about emerging issues in biotechnology public policy, scientific progress, and raising capital, plus methods to benefit from BIO’s membership services.

  • About
    About Us
    Learn about our priorities
    BIO Leadership
    Meet BIO's Senior Leadership and Board of Directors
    Biotech Basics
    Read about biotechnology
    Industry Recognition
    Get to know the outstanding people and companies BIO supports
    Careers @ BIO
    Explore job openings with BIO today
  • Resource Hub
    Latest Resources
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Content Hub
    Biotech News (BIO.News)
    BIO.News Newsletter
    I am BIO Podcast
    BIO Advocacy Toolkit
    Resources Hub
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Webinars
    BIO Microsites
    Clinical Trials: The Power of Participation
    Covid Vaccine Facts
  • Search Results
    Previously Searched
Logo
Logo
Home
Search
  • Policy
    Human HealthPatient AdvocacyInternationalIntellectual PropertyNational SecurityScience & RegulatoryAll Policies
  • Member
    Become a BIO MemberBenefits By Sector
    Human HealthStartupsNon-R&D Companies
    Member DirectoryHave a VoiceMembership EligibilitySavings
  • News & Insights
    Press ReleasesBio.News BlogLetters, Testimony & CommentsAmicus BriefsIndustry Analysis ReportsBiotech JobsEconomic Development Best PracticesIssue BriefsBIO.NewsVideosAll News & Insights
  • Events
    BIO International ConventionBIO Asia-TaiwanAll Events
  • About
    About UsBIO LeadershipBiotech BasicsIndustry RecognitionCareers @ BIO
  • Resource Hub
    Biotech News (BIO.News)BIO.News NewsletterI am BIO PodcastBIO Advocacy ToolkitBIO Early-Stage Resources HubBIO Professional DevelopmentBIO WebinarsClinical Trials: The Power of ParticipationCovid Vaccine Facts
Search Results
Previously Searched
Search Results
Previously Searched
3232 results found
Expand All
Apply All
3232 results found

BIO Statement on HHS Dismissal of CDC Advisory Committee Members
Share
Press Release  •  June 9, 2025
WASHINGTON, D.C. - John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding today’s dismissal of the voting members of the CDC Advisory Committee on Immunization Practices:   “The Advisory Committee on Immunization Practices (ACIP) is vital to ensuring scientific rigor and third-party experts inform decisions about the safe and effective use of vaccines in the US. Under the law, ACIP also plays a critical role determining how the American people access immunizations.  We are greatly concerned about the uncertainty created by the abrupt dismissal of the serving committee members and the loss of years of experience, especially less than three weeks before the next ACIP meeting, with consequential votes on recommendations that will affect Americans’ access to RSV, flu, HPV and other important vaccines. While the advisors serve on the ACIP at the selection and appointment by the Secretary, the removal of committee members will cause significant disruption in this critical process. Immunization reviews take place through working groups over many months, culminating with discussion during a public meeting. A wholesale change of this manner will negatively affect the Committee’s ability to deliberate and make well-informed recommendations, putting American lives at risk.   We agree that transparency is key to restoring trust in immunizations; however, the actions taken today upend a time-tested system that has protected American public health.”  ### 
Read More

Saving lives with measles vaccinations, newborn screenings
Share
Bio.News  •  June 9, 2025
Measles vaccination and screening newborns for treatable diseases are preventive measures that can save lives and health care costs, as we explain in today’s edition. Also, officials share encouraging views during an FDA roundtable on CGT. (707 words, 3 minutes, 32 seconds)
Read More

BioFlorida
Share
BIO Business Solutions - Member Association
Through its partnership with BIO, BioFlorida offers its members the opportunity to take advantage of the BIO Business Solutions® programs listed below. Click on the company name to learn more.There is no fee for BioFlorida members to participate.
Read More

Nature's Building Blocks
Share
Nature's Building Blocks
NBB

A big week in COVID vaccine news
Share
Bio.News  •  June 2, 2025
As June begins, a lot of news: COVID-19 vaccine guidance continues to change, and BIO is dedicating its focus entirely to human health. (929 words, 4 minutes, 38 seconds)
Read More

CSBA Letter to Congressional Leadership Supporting R&D Tax Expensing Legislation
Share
Council for State Biotechnology Associations (CSBA)  •  Letters, Testimony & Comments  •  May 29, 2025

BIO Announces Dedicated Focus on Human Health and Biopharmaceutical Innovation
Share
Press Release  •  May 28, 2025
BIO to Transition Agricultural and Environmental Biotech Workstreams  Key Senior Hires Bolster Focus on Regulatory Affairs, Emerging Companies   and Economic Growth   Washington, DC, May 28, 2025 – The Biotechnology Innovation Organization (BIO) today announced plans to dedicate its focus entirely to human health and to transition the work of its Agriculture and Environment (A&E) section to other organizations.  This change is intended to enable an enhanced strategic focus on each of these respective areas of biotechnology and will be effective July 1, 2025. In support of this transition, BIO announced the hiring of two new senior executives to lead Regulatory Affairs and a new “Center of Excellence” focused on Emerging Companies & Economic Growth.   “The field of biotechnology is increasingly diverse, with great threats and significant opportunities,” said John F. Crowley, President and CEO, BIO. “In consultation with the BIO Executive Committee and the Agriculture and Environment Governing Board, BIO has determined that these organizational changes will enable greater focus and impact on behalf of our healthcare members, and will sharpen our advocacy work on critical policy priorities for the improvement of human health – modernizing the FDA’s regulatory processes; building back a robust biopharmaceutical manufacturing base across the US and our allies; preserving strong IP protections; fostering capital formation; protecting our national security; and enabling 21st Century access to medicines. At the same time, this change will enable A&E member companies to enhance their focus on agricultural and environmental biotech at expert third-party organizations.”   BIO also announced the addition of two new senior leaders to its healthcare team.   Annetta Beauregard will join BIO effective June 9, 2025 as SVP, Science & Regulatory Affairs, where she will spearhead BIO’s regulatory policy strategy and…
Read More

Vaccine news + Lawmakers question HHS budget
Share
Bio.News  •  May 27, 2025
We hope you had a restful Memorial Day weekend. Today, we recap last week’s big vaccine news, what RFK Jr. said on Capitol Hill, and the release of the MAHA report. (776 words, 3 minutes, 52 seconds)
Read More

Progress on PBM reform, ORPHAN CURES Act, and more
Share
Bio.News  •  May 19, 2025
A busy week on Capitol Hill brought promising developments on orphan drugs, PBM reform, tax deductions for R&D, and sustainable aviation fuels. (688 words, 3 minutes, 26 seconds)
Read More

MFN would undermine economic and national security; BIO calls for solutions
Share
Bio.News  •  May 13, 2025
We're back on a Tuesday with what BIO's saying about the Most Favored Nation Executive Order, and what to know about an important markup happening in the House today. (387 words, 1 minute, 57 seconds)
Read More

Pagination

  • First First page
  • Prev Previous page
  • …
  • 30
  • 31
  • 32
  • …
  • Next Next page
  • Last Last page
Biotechnology Innovation Organization
Explore BIO
Policy
Events
About
Industry Insights
Join Now
BIO PAC
For Members
Member Directory
BIO Policy Committees
Cost-Savings Program
BIO Events
BIO Investment and Growth Summit
BIO Partnering™ for Oncology
BIO International Convention
BIO Partnering™ at JPM Week
BIO Patient Advocacy Changemakers Events
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2026 All Rights Reserved
Privacy Policy
Terms of Use
Contact BIO